Session Details

F090 Erythromelalgia: From Diagnosis to Treatment of Pediatric and Adult Patients

Mon, Mar 10, 1:00 PM - 3:00 PM
W207A
2 CME Available Forum NEW
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

In this 2-hour session, participants will gain essential insights into diagnosing this rare condition in both adult and pediatric patients. The session will cover a comprehensive workup plan, enabling attendees to identify key clinical features and underlying causes. Additionally, we will present an effective treatment algorithm tailored to individual patient needs, encompassing both pharmacological and non-pharmacological approaches. Enhance your clinical skills and improve patient outcomes by understanding this complex disorder in a collaborative learning environment.

LEARNING OBJECTIVES

1.

Recognize and diagnose erythromelalgia in pediatric and adult patients.

2.

Develop a comprehensive evaluation plan for patients with erythromelalgia.

3.

Select best therapeutic strategy.

SCHEDULE

5:00 PM

Epidemiology and diagnosis of erythromelalgia in adult patients

Mark D.P. Davis, MD, FAAD

5:30 PM

Role of neurologic testing in the evaluation of erythromelalgia

Paola Sandroni, MD, PhD

5:55 PM

Management of erythromelalgia in adult patients

Julio Cesar Sartori Valinotti, MD, FAAD

6:20 PM

Epidemiology, diagnosis and management of erythromelalgia in pediatric patients

Dawn M.R. Davis, MD, FAAD

6:45 PM

Questions and Answers

SPEAKERS

Dawn M.R. Davis, MD, FAAD

Dawn M.R. Davis, MD, FAAD

Mark D.P. Davis, MD, FAAD

Mark D.P. Davis, MD, FAAD

Paola Sandroni, MD, PhD

Paola Sandroni, MD, PhD

Julio Cesar Sartori Valinotti, MD, FAAD

Julio Cesar Sartori Valinotti, MD, FAAD

HANDOUTS

Login to view handouts

SPEAKER DISCLOSURES

Dawn M.R. Davis, MD, FAAD

No financial relationships exist with ineligible companies.

Mark D.P. Davis, MD, FAAD

No financial relationships exist with ineligible companies.

Paola Sandroni, MD, PhD

No financial relationships exist with ineligible companies.

Julio Cesar Sartori Valinotti, MD, FAAD

No financial relationships exist with ineligible companies.